Resolution

of the Federal Joint Committee on the discontinuation of a benefit assessment procedure according to Section 35a SGB V on Diroximel fumarate (relapsing-remitting multiple sclerosis)

of 6 July 2023

The Federal Joint Committee (G-BA) decided the following at its session on 6 July 2023:

I. The benefit assessment procedure according to Section 35a SGB V for the proprietary medicinal product Vumerity with the active ingredient diroximel fumarate in the therapeutic indication for the treatment of adult patients with relapsing-remitting multiple sclerosis is discontinued.

II. The resolution will enter into force on the day of its publication on the website of the G-BA on 6 July 2023.

The justification to this resolution will be published on the website of the G-BA at www.g-ba.de.

Berlin, 6 July 2023

Federal Joint Committee (G-BA)
in accordance with Section 91 SGB V
The Chair

Prof. Hecken